title: Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide.
abstract: To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3', and tested for its anti-SARS-CoV activity. We found that the supernatants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-alpha and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19+ B cells and CD56+ NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-gamma secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.
authors.affiliation: Department of Molecular Biology, College of Basic Medicine, Jilin University, Changchun 130021, China.
authors.forename: Musheng
authors.initials: M
authors.lastname: Bao
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Wan
authors.forename: Li
authors.initials: L
authors.lastname: Dai
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Hu
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wu
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Deng
authors.forename: Junzhi
authors.initials: J
authors.lastname: Wang
authors.forename: Jianzhu
authors.initials: J
authors.lastname: Chen
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Liu
authors.forename: Yongli
authors.initials: Y
authors.lastname: Yu
authors.forename: Liying
authors.initials: L
authors.lastname: Wang
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology; D002460:Cell Line; D002522:Chlorocebus aethiops; D018899:CpG Islands / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000821:virology; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000821:virology; D008213:Lymphocyte Activation / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology* / Q000517:prevention & control; D014709:Vero Cells
chemical_list: D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides